A Phase 1, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1022 and SCB-1033 in Healthy Older Adults Aged 60-85 Years
Latest Information Update: 24 Jun 2025
At a glance
- Drugs SCB 1022 (Primary) ; SCB 1033 (Primary) ; SCB-1019
- Indications Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Clover Biopharmaceuticals
Most Recent Events
- 17 Jun 2025 According to a Clover Biopharmaceuticals media release, company announced first participants in this trial.
- 17 Jun 2025 Status changed from not yet recruiting to recruiting, according to a Clover Biopharmaceuticals media release.
- 29 May 2025 New trial record